COMPOSITION FOR TREATING ISCHEMIC LIMB DISEASE COMPRISING STEM CELLS DERIVED FROM ADIPOSE TISSUE

• US 20100196329A1
• Filed: 05/09/2008
• Published: 08/05/2010
• Est. Priority Date: 05/25/2007
• Status: Abandoned Application

• Current Assignee: RNL Bio Co., Ltd.
• Original Assignee: RNL Bio Co., Ltd.
• Inventors: Kim, Hyo Eun, Han, Hae Jung, Lee, Hang Young, Ra, Jeong Chan
• Application Number:
  US12/601,809
• Publication Number:
  US 20100196329A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/10 Sulfides; Sulfoxides; Sulfones
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/38 Albumins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/183 Amino acids, e.g. glycine, EDTA or aspartame
• CPC Class Codes: A61K 47/20 containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 47/42 Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein oligopeptides having up to five amino acids A61K47/183; polyamino acids A61K47/34
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Disclosed herein is a cell therapeutic composition for treating ischemic limb diseases, more specifically, disclosed is a cell therapeutic composition for treating ischemic diseases, which contains adipose tissue-derived mesenchymal stem cells and sucrose or mannose as an excipient. The composition induces angiogenesis around closed blood vessels in the ischemic limb lesions, and thus is useful to treat ischemic diseases.

Claims

1. A cell therapeutic composition for treating ischemic diseases, which contains adipose tissue-derived mesenchymal stem cells and an excipient, wherein the concentration of the adipose tissue-derived mesenchymal cells is 1×

10⁵-1×

10⁸ cells/mL, and the excipient is sucrose or mannose.

2. The cell therapeutic composition for treating ischemic diseases according to claim 1, wherein a base for the composition is selected from the group consisting of physiological saline, phosphate buffered saline (PBS) and Hartman-D®

.

3. The cell therapeutic composition for treating ischemic diseases according to claim 1, which additionally contains albumin or human serum as an excipient.

4. The cell therapeutic composition for treating ischemic diseases according to claim 1, which additionally contains EDTA or DMSO as an excipient.

5. The cell therapeutic composition for treating ischemic diseases according to claim 1, which additionally contains a pharmaceutically acceptable amount of at least one additive selected from the group consisting of suspending agents, solubilizing agents, stabilizers, isotonic agents, preservatives, adsorption-preventing agents, surfactants, diluents, vehicles, pH-adjusting agents, analgesic agents, buffering agents, sulfur-containing reducing agents and antioxidants.

6. The cell therapeutic composition for treating ischemic diseases according to claim 2, which additionally contains EDTA or DMSO as an excipient.

7. The cell therapeutic composition for treating ischemic diseases according to claim 3, which additionally contains EDTA or DMSO as an excipient.

8. A method for treating ischemic diseases, the method comprising:

administering the cell therapeutic composition according to claim 1.